2.43
price down icon5.45%   -0.14
pre-market  Vorhandelsmarkt:  2.49   0.06   +2.47%
loading
Schlusskurs vom Vortag:
$2.57
Offen:
$2.6
24-Stunden-Volumen:
734.30K
Relative Volume:
0.31
Marktkapitalisierung:
$260.06M
Einnahmen:
$27.08M
Nettoeinkommen (Verlust:
$-37.00M
KGV:
-4.6731
EPS:
-0.52
Netto-Cashflow:
$-18.46M
1W Leistung:
+1.67%
1M Leistung:
-3.95%
6M Leistung:
+99.18%
1J Leistung:
+113.16%
1-Tages-Spanne:
Value
$2.39
$2.60
1-Wochen-Bereich:
Value
$2.33
$2.60
52-Wochen-Spanne:
Value
$0.9515
$5.17

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name
Firmenname
Aclaris Therapeutics Inc
Name
Telefon
484-324-7933
Name
Adresse
701 LEE ROAD, WAYNE, PA
Name
Mitarbeiter
91
Name
Twitter
@aclaristx
Name
Nächster Verdiensttermin
2024-11-18
Name
Neueste SEC-Einreichungen
Name
ACRS's Discussions on Twitter

Vergleichen Sie ACRS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
ACRS
Aclaris Therapeutics Inc
2.43 260.06M 27.08M -37.00M -18.46M -0.52
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
572.71 219.06B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
210.01 151.02B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
A
Agilent Technologies Inc
147.64 42.12B 6.51B 1.29B 1.37B 4.42
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
209.96 38.11B 15.32B 1.41B 1.96B 7.62
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
460.56 37.71B 3.84B 866.24M 792.60M 10.37

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-23 Hochstufung H.C. Wainwright Neutral → Buy
2024-11-20 Hochstufung Cantor Fitzgerald Neutral → Overweight
2024-11-19 Hochstufung BTIG Research Neutral → Buy
2024-11-19 Hochstufung Jefferies Hold → Buy
2024-11-19 Hochstufung Leerink Partners Market Perform → Outperform
2024-11-18 Hochstufung Piper Sandler Neutral → Overweight
2024-01-22 Herabstufung H.C. Wainwright Buy → Neutral
2023-11-13 Herabstufung William Blair Outperform → Mkt Perform
2023-10-03 Eingeleitet Evercore ISI Outperform
2022-12-14 Eingeleitet Stifel Buy
2022-12-01 Eingeleitet Goldman Buy
2022-10-06 Eingeleitet BTIG Research Buy
2021-07-23 Fortgesetzt Jefferies Buy
2021-06-15 Eingeleitet Piper Sandler Overweight
2021-04-21 Eingeleitet H.C. Wainwright Buy
2019-10-22 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-09-06 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2019-06-27 Herabstufung SVB Leerink Outperform → Mkt Perform
2019-05-06 Eingeleitet SVB Leerink Outperform
2018-03-28 Fortgesetzt Leerink Partners Outperform
2018-02-09 Eingeleitet Guggenheim Buy
2017-06-16 Eingeleitet Cantor Fitzgerald Overweight
2016-11-29 Eingeleitet Leerink Partners Outperform
2016-09-30 Eingeleitet JMP Securities Mkt Outperform
2016-06-10 Eingeleitet Guggenheim Buy
2015-11-02 Eingeleitet Citigroup Buy
2015-11-02 Eingeleitet Jefferies Buy
Alle ansehen

Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten

pulisher
06:20 AM

What is Leerink Partnrs’ Forecast for ACRS FY2025 Earnings? - Armenian Reporter

06:20 AM
pulisher
05:56 AM

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Analysts - MarketBeat

05:56 AM
pulisher
Feb 06, 2025

Aclaris Therapeutics Inc [ACRS] Records 50-Day SMA of $2.98 - Knox Daily

Feb 06, 2025
pulisher
Feb 05, 2025

Aclaris Therapeutics forms new Scientific Advisory Board - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

The Aclaris Therapeutics Inc (ACRS) had a good session last reading, didn’t it? - US Post News

Feb 05, 2025
pulisher
Feb 04, 2025

Aclaris Therapeutics Inc (ACRS)’s Market Momentum: Closing Strong at 2.40, Down -3.23 - The Dwinnex

Feb 04, 2025
pulisher
Feb 04, 2025

Healthy Upside Potential: Aclaris Therapeutics Inc (ACRS) - SETE News

Feb 04, 2025
pulisher
Feb 04, 2025

Market Insight: Eterna Therapeutics Inc (ERNA)’s Notable Drop, Closing at 0.36 - The Dwinnex

Feb 04, 2025
pulisher
Feb 02, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Cantor Fitzgerald - Defense World

Feb 02, 2025
pulisher
Feb 01, 2025

Aclaris Therapeutics Forms Scientific Advisory Board with Renowned Pulmonology Experts - MSN

Feb 01, 2025
pulisher
Feb 01, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Strong-Buy at Cantor Fitzgerald - MarketBeat

Feb 01, 2025
pulisher
Feb 01, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 12.7% in January - Defense World

Feb 01, 2025
pulisher
Jan 31, 2025

StockNews.com Downgrades Aclaris Therapeutics (NASDAQ:ACRS) to Sell - Defense World

Jan 31, 2025
pulisher
Jan 31, 2025

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - GlobeNewswire

Jan 31, 2025
pulisher
Jan 30, 2025

Aclaris Therapeutics forms new Scientific Advisory Board By Investing.com - Investing.com Canada

Jan 30, 2025
pulisher
Jan 30, 2025

Aclaris Therapeutics Appoints Marianne Mann and Zuzana Diamant to Scientific Advisory Board - citybiz

Jan 30, 2025
pulisher
Jan 25, 2025

Assenagon Asset Management S.A. Acquires 211,585 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Jan 25, 2025
pulisher
Jan 25, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Purchased by Assenagon Asset Management S.A. - MarketBeat

Jan 25, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Comments on ACRS FY2025 Earnings - Defense World

Jan 23, 2025
pulisher
Jan 22, 2025

Cantor Fitzgerald Weighs in on ACRS FY2025 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 18, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 12.7% in December - MarketBeat

Jan 18, 2025
pulisher
Jan 16, 2025

Hair Treatment Drug Market Is Booming Worldwide | 3S Bio, Inc.,AbbVie,Aclaris Therapeutics, Inc.,Cipla, Inc. - openPR

Jan 16, 2025
pulisher
Jan 16, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $11.00 Average Target Price from Brokerages - Defense World

Jan 16, 2025
pulisher
Jan 15, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Jane Street Group LLC - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

Jane Street Group LLC Reduces Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Jan 15, 2025
pulisher
Jan 13, 2025

Aclaris Therapeutics Highlights Drug Progress and Financial Strength - TipRanks

Jan 13, 2025
pulisher
Jan 13, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Jan 13, 2025
pulisher
Jan 11, 2025

Geode Capital Management LLC Grows Stock Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Jan 11, 2025
pulisher
Jan 08, 2025

Aclaris Therapeutics Awards Stock Options to Attract Top Talent - MSN

Jan 08, 2025
pulisher
Jan 06, 2025

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Jan 06, 2025
pulisher
Jan 06, 2025

Hair Loss Treatment Market Is Booming Worldwide 2024-2031 | Viviscal, Cipla Inc., Aclaris Therapeutics - openPR

Jan 06, 2025
pulisher
Jan 04, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by State Street Corp - Defense World

Jan 04, 2025
pulisher
Jan 03, 2025

Aclaris sells OLUMIANT royalties and milestones to OMERS life sciences - MSN

Jan 03, 2025
pulisher
Jan 03, 2025

HC Wainwright & Co. Upgrades Aclaris Therapeutics (ACRS) - MSN

Jan 03, 2025
pulisher
Jan 01, 2025

ACRS LOSS NOTICE: ROSEN, A LEADING FIRM, Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the FirmACRS - AccessWire

Jan 01, 2025
pulisher
Dec 31, 2024

INVESTOR ALERTAclaris Therapeutics, Inc. (ACRS)Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: September 30, 2019 - AccessWire

Dec 31, 2024
pulisher
Dec 31, 2024

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Update - Defense World

Dec 31, 2024
pulisher
Dec 29, 2024

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 27.4% in December - MarketBeat

Dec 29, 2024
pulisher
Dec 26, 2024

Research Analysts Issue Forecasts for ACRS FY2024 Earnings - Defense World

Dec 26, 2024
pulisher
Dec 25, 2024

HC Wainwright Has Bullish Estimate for ACRS FY2024 Earnings - MarketBeat

Dec 25, 2024
pulisher
Dec 24, 2024

Aclaris Therapeutics shares upgraded to Buy on strong growth potential in AD and asthma - Investing.com Nigeria

Dec 24, 2024
pulisher
Dec 24, 2024

Aclaris Therapeutics shares upgraded to Buy on strong growth potential in AD and asthma By Investing.com - Investing.com South Africa

Dec 24, 2024
pulisher
Dec 24, 2024

Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to Buy at HC Wainwright - Defense World

Dec 24, 2024

Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Aclaris Therapeutics Inc-Aktie (ACRS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Mehra Anand
Director
Nov 19 '24
Buy
2.25
666,666
1,499,998
710,030
Walker Neal
INTERIM PRESIDENT AND CEO
Aug 09 '24
Option Exercise
0.72
43,548
31,355
1,356,153
Leonard Braden Michael
10% Owner
Aug 05 '24
Buy
1.24
206,025
256,357
14,250,000
Leonard Braden Michael
10% Owner
Aug 02 '24
Buy
1.29
167,544
216,400
14,043,975
Leonard Braden Michael
10% Owner
Jul 30 '24
Buy
1.30
173,730
226,370
13,776,421
Leonard Braden Michael
10% Owner
Jul 31 '24
Buy
1.33
100,000
132,640
13,876,421
Leonard Braden Michael
10% Owner
Jul 18 '24
Buy
1.30
130,317
169,555
13,578,286
Leonard Braden Michael
10% Owner
Jul 22 '24
Buy
1.33
17,716
23,557
13,602,691
Leonard Braden Michael
10% Owner
Jul 19 '24
Buy
1.30
6,689
8,696
13,584,975
Leonard Braden Michael
10% Owner
Jul 03 '24
Buy
1.16
143,288
166,071
13,324,952
$122.80
price down icon 1.51%
diagnostics_research LH
$247.74
price down icon 0.90%
$175.14
price down icon 1.05%
diagnostics_research WAT
$410.95
price down icon 0.76%
diagnostics_research MTD
$1,357.26
price down icon 0.46%
$460.56
price down icon 1.71%
Kapitalisierung:     |  Volumen (24h):